Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 605 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.
Ascentage Pharma Group International의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Ascentage Pharma Group International 주요 수익원은 Intellectual Property Rights이며, 최신 수익 발표에서 수익은 735,553,749입니다. 지역별로는 Switzerland이 Ascentage Pharma Group International의 주요 시장이며, 수익은 735,553,749입니다.
Ascentage Pharma Group International은 수익성이 있나요?
no, 최신 재무제표에 따르면 Ascentage Pharma Group International의 순손실은 $-405입니다.
Ascentage Pharma Group International에 부채가 있나요?
예, Ascentage Pharma Group International의 부채는 2,353입니다.
Ascentage Pharma Group International의 발행 주식은 몇 주인가요?
Ascentage Pharma Group International의 총 발행 주식은 315.22주입니다.